Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
DataMEDS AIMEDS -3.35% EBIT per Share is $-43.23 as of Mar. 2026. The stock has 6 warning signs investors should review. Among 107 Medical Distribution companies, DataMEDS AI ranks worse than 100% on this metric.
DataMEDS AI's EBIT per Share for the
three
months ended in Mar. 2026 was $-2.71.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $-43.23.
During the past 3 years, the average EBIT per Share Growth Rate was -150.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for DataMEDS AI's EBIT per Share or its related term are showing as below:
MEDS'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -150.9 Med: -150.9 Max: -150.9
Current: -150.9
During the past 4 years, the highest 3-Year average EBIT per Share Growth Rate of DataMEDS AI was -150.90% per year. The lowest was -150.90% per year. And the median was -150.90% per year.
MEDS's 3-Year EBIT Growth Rate is ranked worse than 100% of 107
companies
in the Medical Distribution industry
Industry Median: 2.7
vs MEDS: -150.90
DataMEDS AI's EBIT for the
three
months ended in Mar. 2026 was $-5.67 Mil.
DataMEDS AI (NAS:MEDS) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
DataMEDS AI EBIT per Share Related Terms
DataMEDS AI EBIT per Share Historical Data
* Premium members only.
The historical data trend for DataMEDS AI's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-43.23
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DataMEDS AI (MEDS) has a EBIT per Share of $-43.23 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on DataMEDS AI and its competitors. According to the industry distribution chart, DataMEDS AI ranks #107 out of 107 companies in the Medical Distribution industry.
Is DataMEDS AI's EBIT per Share too high?
DataMEDS AI's current EBIT per Share is $-43.23. Based on the distribution chart, DataMEDS AI ranks #107 out of 107 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers.
How does DataMEDS AI's EBIT per Share compare to HEWA and BLMH?
According to the Medical Distribution industry distribution chart, DataMEDS AI ranks #107 out of 107 companies for EBIT per Share. This places DataMEDS AI in the lower half of its industry. The industry median EBIT per Share is 2.70. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Distribution company?
The median EBIT per Share among Medical Distribution companies is 2.70, based on 107 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on DataMEDS AI and its competitors. For the Medical Distribution industry, the median EBIT per Share is 2.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. DataMEDS AI's current EBIT per Share is $-43.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DataMEDS AI stock overvalued right now?
DataMEDS AI (MEDS) has a current EBIT per Share of $-43.23. The current EBIT per Share is $-43.23. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For DataMEDS AI (MEDS), the current EBIT per Share is $-43.23 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Wellgistics Health Inc is a healthcare technology and pharmaceutical logistics company. It simplifies the logistics of prescription fulfillment from the manufacturer and provider to the patient. The company seeks to be a micro health ecosystem, with a portfolio comprising a pharmacy, wholesale operations, and a technology division that provides a novel platform for hub and clinical services. It is focused on improving the lives of patients while delivering solutions for pharmacies, providers, pharmaceutical manufacturers, and payors.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEDS has been successfully added to your 
